Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-10-23

AUTHORS

Yohann Bala, Joseph Kohles, Robert R. Recker, Georges Boivin

ABSTRACT

Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34 months with an oral placebo (n = 36), 2.5 mg daily oral ibandronate (n = 40), or 20 mg intermittent oral ibandronate (n = 34). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34 months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34 months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r = 0.59–0.65, p < 0.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization. More... »

PAGES

6-14

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6

DOI

http://dx.doi.org/10.1007/s00223-012-9658-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036510668

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23090678


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biopsy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fractures, Bone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ibandronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regression Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reproducibility of Results", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.25697.3f", 
          "name": [
            "INSERM UMR 1033 Equipe \u201cQualit\u00e9 Osseuse et Marqueurs Biologiques\u201d, Facult\u00e9 de M\u00e9decine Lyon Est, Claude Bernard (Domaine Laennec), Universit\u00e9 de Lyon, 7\u201311 rue Guillaume Paradin, 69372, Lyon Cedex 08, France", 
            "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bala", 
        "givenName": "Yohann", 
        "id": "sg:person.01260243176.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260243176.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hoffmann-LaRoche, 07110, Nutley, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Hoffmann-LaRoche, 07110, Nutley, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kohles", 
        "givenName": "Joseph", 
        "id": "sg:person.01150513510.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150513510.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osteoporosis Research Center, 68131, Omaha, NE, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Osteoporosis Research Center, 68131, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Recker", 
        "givenName": "Robert R.", 
        "id": "sg:person.016325222544.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.25697.3f", 
          "name": [
            "INSERM UMR 1033 Equipe \u201cQualit\u00e9 Osseuse et Marqueurs Biologiques\u201d, Facult\u00e9 de M\u00e9decine Lyon Est, Claude Bernard (Domaine Laennec), Universit\u00e9 de Lyon, 7\u201311 rue Guillaume Paradin, 69372, Lyon Cedex 08, France", 
            "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boivin", 
        "givenName": "Georges", 
        "id": "sg:person.01270330331.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270330331.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-007-0540-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051377661", 
          "https://doi.org/10.1007/s00198-007-0540-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-005-2035-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041631602", 
          "https://doi.org/10.1007/s00198-005-2035-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1018671823059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017861302", 
          "https://doi.org/10.1023/a:1018671823059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-007-0462-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029822466", 
          "https://doi.org/10.1007/s00198-007-0462-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1530-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045100855", 
          "https://doi.org/10.1007/s00198-003-1530-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1557/jmr.1999.0490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053186687", 
          "https://doi.org/10.1557/jmr.1999.0490"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10-23", 
    "datePublishedReg": "2012-10-23", 
    "description": "Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34\u00a0months with an oral placebo (n\u00a0=\u00a036), 2.5\u00a0mg daily oral ibandronate (n\u00a0=\u00a040), or 20\u00a0mg intermittent oral ibandronate (n\u00a0=\u00a034). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34\u00a0months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34\u00a0months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r\u00a0=\u00a00.59\u20130.65, p\u00a0<\u00a00.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00223-012-9658-6", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1089641", 
        "issn": [
          "0171-967X", 
          "1432-0827"
        ], 
        "name": "Calcified Tissue International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "92"
      }
    ], 
    "keywords": [
      "annual cumulative exposure", 
      "intermittent oral ibandronate", 
      "oral ibandronate", 
      "higher bone mineral density", 
      "new vertebral fractures", 
      "daily oral ibandronate", 
      "low bone turnover", 
      "postmenopausal osteoporotic women", 
      "months of treatment", 
      "bone mineral density", 
      "oral placebo", 
      "osteoporotic women", 
      "vertebral fractures", 
      "iliac biopsies", 
      "bone turnover", 
      "therapeutic doses", 
      "mineral density", 
      "ibandronate", 
      "placebo", 
      "analysis of covariance", 
      "cumulative exposure", 
      "total bone", 
      "PMOP women", 
      "months", 
      "regimens", 
      "women", 
      "bone tissue", 
      "bone", 
      "degree of mineralization", 
      "linear regression", 
      "levels", 
      "biopsy", 
      "patients", 
      "group", 
      "incidence", 
      "doses", 
      "treatment", 
      "total", 
      "tissue", 
      "y-intercept", 
      "exposure", 
      "unit level", 
      "fractures", 
      "regression", 
      "aim", 
      "changes", 
      "half", 
      "differences", 
      "study", 
      "DMB", 
      "effect", 
      "turnover", 
      "secondary mineralization", 
      "global level", 
      "degree", 
      "analysis", 
      "intercept", 
      "focal level", 
      "covariance", 
      "mineralization", 
      "distribution", 
      "density", 
      "properties", 
      "HV", 
      "micromechanical properties", 
      "BSU", 
      "microhardness"
    ], 
    "name": "Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization", 
    "pagination": "6-14", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036510668"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00223-012-9658-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23090678"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00223-012-9658-6", 
      "https://app.dimensions.ai/details/publication/pub.1036510668"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_585.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00223-012-9658-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'


 

This table displays all metadata directly associated to this object as RDF triples.

248 TRIPLES      21 PREDICATES      115 URIs      101 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00223-012-9658-6 schema:about N316074b0a37e466e90bd9a3bb58788cf
2 N3725f7b55fd34d438ccf72d72ffb30da
3 N38bd4f41e76b4e95b4a7c740bedfc01c
4 N434d3400df4046dda8beb4ddae361e71
5 N4d3f3e71911745eeb532048fb331c428
6 N4d6637d4dbda44a780ae2988d93888a9
7 N58e7c355aaf9485dade46dfe5a51312e
8 N6d831f35d42749fa8f77aa03661f8c76
9 N6fd1dbfb14e04389b94019db9920ffc0
10 N765db9da3c624367935eee542dfc3a49
11 N9463ba9a246145a79c3c507eda9b7a94
12 Na98ea71c48584d8181befde42f42d33f
13 Nada134124d504622ad29781c102fd7b3
14 Naf3743a7b8c440d5b01ce06f28b6ff93
15 Nc567870ae09f4fa6bf1008d6dfdbbdf4
16 Ndd13e1c7d9d8412696335e4406314ff9
17 Nee2820e32e57487ca642d3d24f852ea0
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Nb8bdf16921e5400692b10c74cf5d9216
21 schema:citation sg:pub.10.1007/s00198-003-1530-0
22 sg:pub.10.1007/s00198-005-2035-9
23 sg:pub.10.1007/s00198-007-0462-5
24 sg:pub.10.1007/s00198-007-0540-8
25 sg:pub.10.1023/a:1018671823059
26 sg:pub.10.1557/jmr.1999.0490
27 schema:datePublished 2012-10-23
28 schema:datePublishedReg 2012-10-23
29 schema:description Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34 months with an oral placebo (n = 36), 2.5 mg daily oral ibandronate (n = 40), or 20 mg intermittent oral ibandronate (n = 34). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34 months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34 months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r = 0.59–0.65, p < 0.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization.
30 schema:genre article
31 schema:isAccessibleForFree false
32 schema:isPartOf N784e3a1ac2334866a82010e852905303
33 Nde53cca8469e482d9299cafc2830ce3b
34 sg:journal.1089641
35 schema:keywords BSU
36 DMB
37 HV
38 PMOP women
39 aim
40 analysis
41 analysis of covariance
42 annual cumulative exposure
43 biopsy
44 bone
45 bone mineral density
46 bone tissue
47 bone turnover
48 changes
49 covariance
50 cumulative exposure
51 daily oral ibandronate
52 degree
53 degree of mineralization
54 density
55 differences
56 distribution
57 doses
58 effect
59 exposure
60 focal level
61 fractures
62 global level
63 group
64 half
65 higher bone mineral density
66 ibandronate
67 iliac biopsies
68 incidence
69 intercept
70 intermittent oral ibandronate
71 levels
72 linear regression
73 low bone turnover
74 microhardness
75 micromechanical properties
76 mineral density
77 mineralization
78 months
79 months of treatment
80 new vertebral fractures
81 oral ibandronate
82 oral placebo
83 osteoporotic women
84 patients
85 placebo
86 postmenopausal osteoporotic women
87 properties
88 regimens
89 regression
90 secondary mineralization
91 study
92 therapeutic doses
93 tissue
94 total
95 total bone
96 treatment
97 turnover
98 unit level
99 vertebral fractures
100 women
101 y-intercept
102 schema:name Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization
103 schema:pagination 6-14
104 schema:productId N8618d9262fd4428fa0e10c2110e466c5
105 Nba1ed501f06442a88dc0e588e8f013e5
106 Nf937ff07b77141c884eeadec5fe48b3c
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036510668
108 https://doi.org/10.1007/s00223-012-9658-6
109 schema:sdDatePublished 2022-10-01T06:38
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N080be974cef447689ac0b09f3e091165
112 schema:url https://doi.org/10.1007/s00223-012-9658-6
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N080be974cef447689ac0b09f3e091165 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 N316074b0a37e466e90bd9a3bb58788cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Treatment Outcome
120 rdf:type schema:DefinedTerm
121 N3725f7b55fd34d438ccf72d72ffb30da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Middle Aged
123 rdf:type schema:DefinedTerm
124 N38bd4f41e76b4e95b4a7c740bedfc01c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Osteoporosis, Postmenopausal
126 rdf:type schema:DefinedTerm
127 N434d3400df4046dda8beb4ddae361e71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Double-Blind Method
129 rdf:type schema:DefinedTerm
130 N4d3f3e71911745eeb532048fb331c428 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Aged
132 rdf:type schema:DefinedTerm
133 N4d6637d4dbda44a780ae2988d93888a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Bone Density Conservation Agents
135 rdf:type schema:DefinedTerm
136 N58e7c355aaf9485dade46dfe5a51312e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Humans
138 rdf:type schema:DefinedTerm
139 N6636538154434aa98a6382934ff90c4a rdf:first sg:person.016325222544.69
140 rdf:rest N6efcb80d503347a4ae8c7c25d3843610
141 N6d831f35d42749fa8f77aa03661f8c76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Bone Density
143 rdf:type schema:DefinedTerm
144 N6efcb80d503347a4ae8c7c25d3843610 rdf:first sg:person.01270330331.76
145 rdf:rest rdf:nil
146 N6fd1dbfb14e04389b94019db9920ffc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Ibandronic Acid
148 rdf:type schema:DefinedTerm
149 N765db9da3c624367935eee542dfc3a49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Placebos
151 rdf:type schema:DefinedTerm
152 N784e3a1ac2334866a82010e852905303 schema:volumeNumber 92
153 rdf:type schema:PublicationVolume
154 N8618d9262fd4428fa0e10c2110e466c5 schema:name dimensions_id
155 schema:value pub.1036510668
156 rdf:type schema:PropertyValue
157 N9463ba9a246145a79c3c507eda9b7a94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Female
159 rdf:type schema:DefinedTerm
160 Na98ea71c48584d8181befde42f42d33f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Regression Analysis
162 rdf:type schema:DefinedTerm
163 Nada134124d504622ad29781c102fd7b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Reproducibility of Results
165 rdf:type schema:DefinedTerm
166 Naf3743a7b8c440d5b01ce06f28b6ff93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Diphosphonates
168 rdf:type schema:DefinedTerm
169 Nb8bdf16921e5400692b10c74cf5d9216 rdf:first sg:person.01260243176.80
170 rdf:rest Ndf3a2d97a9f84de5a16961d7ee6d5419
171 Nba1ed501f06442a88dc0e588e8f013e5 schema:name doi
172 schema:value 10.1007/s00223-012-9658-6
173 rdf:type schema:PropertyValue
174 Nc567870ae09f4fa6bf1008d6dfdbbdf4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Fractures, Bone
176 rdf:type schema:DefinedTerm
177 Ndd13e1c7d9d8412696335e4406314ff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Administration, Oral
179 rdf:type schema:DefinedTerm
180 Nde53cca8469e482d9299cafc2830ce3b schema:issueNumber 1
181 rdf:type schema:PublicationIssue
182 Ndf3a2d97a9f84de5a16961d7ee6d5419 rdf:first sg:person.01150513510.45
183 rdf:rest N6636538154434aa98a6382934ff90c4a
184 Nee2820e32e57487ca642d3d24f852ea0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Biopsy
186 rdf:type schema:DefinedTerm
187 Nf937ff07b77141c884eeadec5fe48b3c schema:name pubmed_id
188 schema:value 23090678
189 rdf:type schema:PropertyValue
190 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
191 schema:name Medical and Health Sciences
192 rdf:type schema:DefinedTerm
193 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
194 schema:name Clinical Sciences
195 rdf:type schema:DefinedTerm
196 sg:journal.1089641 schema:issn 0171-967X
197 1432-0827
198 schema:name Calcified Tissue International
199 schema:publisher Springer Nature
200 rdf:type schema:Periodical
201 sg:person.01150513510.45 schema:affiliation grid-institutes:grid.418158.1
202 schema:familyName Kohles
203 schema:givenName Joseph
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150513510.45
205 rdf:type schema:Person
206 sg:person.01260243176.80 schema:affiliation grid-institutes:grid.25697.3f
207 schema:familyName Bala
208 schema:givenName Yohann
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260243176.80
210 rdf:type schema:Person
211 sg:person.01270330331.76 schema:affiliation grid-institutes:grid.25697.3f
212 schema:familyName Boivin
213 schema:givenName Georges
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270330331.76
215 rdf:type schema:Person
216 sg:person.016325222544.69 schema:affiliation grid-institutes:None
217 schema:familyName Recker
218 schema:givenName Robert R.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69
220 rdf:type schema:Person
221 sg:pub.10.1007/s00198-003-1530-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045100855
222 https://doi.org/10.1007/s00198-003-1530-0
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s00198-005-2035-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041631602
225 https://doi.org/10.1007/s00198-005-2035-9
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s00198-007-0462-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029822466
228 https://doi.org/10.1007/s00198-007-0462-5
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s00198-007-0540-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051377661
231 https://doi.org/10.1007/s00198-007-0540-8
232 rdf:type schema:CreativeWork
233 sg:pub.10.1023/a:1018671823059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017861302
234 https://doi.org/10.1023/a:1018671823059
235 rdf:type schema:CreativeWork
236 sg:pub.10.1557/jmr.1999.0490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053186687
237 https://doi.org/10.1557/jmr.1999.0490
238 rdf:type schema:CreativeWork
239 grid-institutes:None schema:alternateName Osteoporosis Research Center, 68131, Omaha, NE, USA
240 schema:name Osteoporosis Research Center, 68131, Omaha, NE, USA
241 rdf:type schema:Organization
242 grid-institutes:grid.25697.3f schema:alternateName Université de Lyon, UMR 1033, 69008, Lyon, France
243 schema:name INSERM UMR 1033 Equipe “Qualité Osseuse et Marqueurs Biologiques”, Faculté de Médecine Lyon Est, Claude Bernard (Domaine Laennec), Université de Lyon, 7–11 rue Guillaume Paradin, 69372, Lyon Cedex 08, France
244 Université de Lyon, UMR 1033, 69008, Lyon, France
245 rdf:type schema:Organization
246 grid-institutes:grid.418158.1 schema:alternateName Hoffmann-LaRoche, 07110, Nutley, NJ, USA
247 schema:name Hoffmann-LaRoche, 07110, Nutley, NJ, USA
248 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...